Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 93 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active CR Clear all
Completed Not applicable Interventional Results available

Telehealth-enhanced Hybrid Cardiac Rehabilitation Among Acute Coronary Syndrome Survivors

NCT05328375
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction
Interventions
Telehealth-enhanced Hybrid CR, Traditional CR
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 23, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Results available

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

NCT00354172
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI)
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Muscle for Functional Independence Trial

NCT01049698
View directory record Official record
Conditions
Obesity
Interventions
Resistance Training, Resistance Training + Diet
Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
65 Years to 79 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 23, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs

NCT00683436
View directory record Official record
Conditions
Primary Insomnia
Interventions
Adipiplon, Placebo, Ambien CR
Drug
Lead sponsor
Neurogen Corporation
Industry
Eligibility
21 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Pembroke Pines, Florida • South Miami, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2008 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

Rehabilitation at Home Using Mobile Health In Older Adults After Hospitalization for Ischemic Heart Disease

NCT03978130
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
mHealth-CR
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years to 110 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Worcester, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 1Phase 2 Interventional

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

NCT00911560
View directory record Official record
Conditions
Neuroblastoma
Interventions
adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH, oral β-glucan
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cereset Research Long-Term Healthcare Worker Study

NCT05994261
View directory record Official record
Conditions
Stress, Anxiety, Autonomic Dysregulation, Acoustic Stimulation, Hyperarousal, Health Personnel
Interventions
Cereset Research
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 100 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Recruiting Phase 2 Interventional

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT03516617
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Laboratory Biomarker Analysis, Obinutuzumab, Patient Observation, Quality-of-Life Assessment
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

NCT01124864
View directory record Official record
Conditions
Non-small-cell Lung Cancer
Interventions
AUY922
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Rockville, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 23, 2026, 5:46 PM EDT
Terminated Phase 4 Interventional Results available

Brief Intervention to Reduce Fear of Public Speaking

NCT02790736
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
propranolol, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin

NCT03804983
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Hybrid Closed Loop (HCL), Control-IQ with MyTDI
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 18 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)

NCT00483496
View directory record Official record
Conditions
Idiopathic Solar Urticaria
Interventions
Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209), Ti02 pigmentary 3% alone (formula RV3131A-MV1211), bisoctrizole 10% alone (formula RV3131A-MV1237), Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213), Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329), Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212), Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)], V0096 CR vehicle (formula RV3131A-MV1197)
Drug
Lead sponsor
Orfagen
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma

NCT02753764
View directory record Official record
Conditions
Corticosteroid Resistant (CR) Asthmatics
Interventions
AZD7624, prednisone, Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 23, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Results available

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma

NCT01183884
View directory record Official record
Conditions
Neuroblastoma
Interventions
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Months and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cereset Research In Healthcare Workers During COVID-19

NCT04682197
View directory record Official record
Conditions
Health Personnel, Stress, Anxiety, Insomnia, Hyperarousal, Corona Virus Infection, Covid19
Interventions
Cereset Research
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

NCT00111007
View directory record Official record
Conditions
Melanoma
Interventions
Sorafenib (Nexavar, BAY43-9006), Carboplatin/Paclitaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Not applicable Interventional

Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment

NCT05498493
View directory record Official record
Conditions
Cognitive Impairment
Interventions
Cognitive Rehabilitation, Brain Health Education Program
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 23, 2026, 5:46 PM EDT
Not listed Not applicable Interventional

Using a mHealth Intervention to Promote Physical Activity in Phase III Cardiac Rehabilitation Clients

NCT05795036
View directory record Official record
Conditions
Cardiac Rehabilitation, Physical Activity
Interventions
mHealth 1, mHealth 2
Device
Lead sponsor
AdventHealth University
Other
Eligibility
18 Years to 99 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

A Study Comparing the Analgesic Activity of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Placebo in Subjects With Pain Following Bunionectomy Surgery

NCT00404391
View directory record Official record
Conditions
Pain
Interventions
Hydrocodone/Acetaminophen Extended Release, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
4
States / cities
Owing Mills, Maryland • Austin, Texas • San Marcos, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2011 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 4 Interventional

Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)

NCT00610909
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Paroxetine CR, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 23, 2026, 5:46 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
1,328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
87
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar Disorder

NCT01934972
View directory record Official record
Conditions
Bipolar Disorder
Interventions
CR + DCS (D-cycloserine), CR + placebo
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 23, 2026, 5:46 PM EDT
Terminated Not applicable Interventional Results available

Evaluation of Using Vibrotactile Coordinated Reset for Management of Parkinson's Disease

NCT03857867
View directory record Official record
Conditions
Parkinson Disease
Interventions
Tactile Stimulation Glove
Device
Lead sponsor
Peter Tass, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating Fitness Interventions in the Elderly (INFINITE)

NCT01048736
View directory record Official record
Conditions
Obesity, Older Adults, Sedentary
Interventions
Exercise Only, Exercise + Diet
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 23, 2026, 5:46 PM EDT